iTOL-100

Treg Modulation Designed for Durable, Localized Immune Tolerance

iTOL-100 is an off-the-shelf immune tolerance platform designed to protect transplanted cells, tissues and organoids from immune-mediated rejection. By modulating the immune response at the site of implantation, iTOL-100 is designed to support durable, functional engraftment without the need for lifelong systemic immunosuppression.

Key Highlights

• Durable and Localized Immune Tolerance
  • Designed to promote durable Treg responses at the site of implantation.
• Long-Term Graft Survival and Function
  • Supports the survival and function of transplanted cells, tissues and organoids.
• Reduced Reliance on Chronic Immunosuppression
  • Designed to eliminate the need for lifelong systemic immunosuppression and the accompanying use of anti-infective drugs.
• Broad Platform Potential
  • An off-the-shelf platform with the potential to support multiple cell, organoid and organ therapies.

How iTOL-100 Works

Localized FasL-mediated immune modulation designed to selectively eliminate activated effector T-cells

iTOL-100 combines SA-FasL with a biotin-PEG microgel that is co-administered with transplanted cells or organoids at the site of implantation. FasL displayed on the microgel surface binds to the Fas receptor on activated T cells, triggering apoptosis and reducing localized immune attack. This localized immune remodeling promotes durable Treg responses and long-term immune tolerance. By acting at the transplant site, iTOL-100 is designed to protect implanted cells and tissues while supporting durable, functional engraftment.

The Fundamental Barrier to Cell and Organ Therapies

Cell, organoid and organ therapies have the potential to replace damaged or dysfunctional tissue and restore critical biological functions. However, transplanted cells and tissues remain vulnerable to recognition and attack by the recipient’s immune system.

Immune-mediated rejection can impair graft function, limit long-term durability and ultimately lead to graft failure. Current approaches often rely on lifelong systemic immunosuppression, which suppresses the entire immune system without creating durable immune tolerance.

The Burden of Lifelong Systemic Immunosuppression